Evidence of monoclonal antibodies effectively neutralizing SARS-CoV-2 variants Evolving variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become a growing concern worldwide for their rapid transmission and ability to cause severe infection. New research led by Ronit Rosenfeld from the Israel Institute for Biological Research confirms evidence that specific monoclonal antibodies can bind to the receptor-binding domain of the B.1.1.7 and B.1.351 variants and effectively neutralize them. The study “The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against novel viral variants” is available as a preprint on the bioRxiv* server, while the article undergoes peer review.